BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29749711)

  • 21. Clinical impact of MDR1-expression in testicular germ cell cancer.
    Schrader AJ; Seger M; Konrad L; Olbert P; Hegele A; Hofmann R; Heidenreich A
    Exp Oncol; 2007 Sep; 29(3):212-6. PubMed ID: 18004247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.
    Lobo J; Gillis AJM; van den Berg A; Looijenga LHJ
    BMC Cancer; 2020 Aug; 20(1):728. PubMed ID: 32758242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific immune cell and cytokine characteristics of human testicular germ cell neoplasia.
    Klein B; Haggeney T; Fietz D; Indumathy S; Loveland KL; Hedger M; Kliesch S; Weidner W; Bergmann M; Schuppe HC
    Hum Reprod; 2016 Oct; 31(10):2192-202. PubMed ID: 27609978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of CD34 antigen in testicular mixed germ cell tumor.
    Hamazaki S; Okada S
    Pathol Int; 2003 Dec; 53(12):853-7. PubMed ID: 14629751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.
    Cost NG; Lubahn JD; Adibi M; Romman A; Wickiser JE; Raj GV; Sagalowsky AI; Margulis V
    J Urol; 2014 May; 191(5 Suppl):1485-90. PubMed ID: 24679874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor-binding fragment-associated gene 9 expression and its clinical significance in human testicular cancer.
    Fujimura T; Takahashi S; Urano T; Xiaoqiang L; Ogushi T; Muramatsu M; Ouchi Y; Kitamura T; Homma Y; Inoue S
    Int J Urol; 2009 Mar; 16(3):329-32. PubMed ID: 19207611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
    Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
    Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glypican 3: a novel marker in testicular germ cell tumors.
    Zynger DL; Dimov ND; Luan C; Teh BT; Yang XJ
    Am J Surg Pathol; 2006 Dec; 30(12):1570-5. PubMed ID: 17122513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
    Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
    Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
    Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
    Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma.
    Du R; Wu S; Lv X; Fang H; Wu S; Kang J
    J Exp Clin Cancer Res; 2014 Dec; 33(1):105. PubMed ID: 25499255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors.
    Patel HD; Singla N; Ghandour RA; Freifeld Y; Cheaib JG; Woldu SL; Pierorazio PM; Bagrodia A
    Cancer; 2019 Nov; 125(22):3947-3952. PubMed ID: 31355922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center.
    Necchi A; Farè E; Vullo SL; Giannatempo P; Raggi D; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Verzoni E; Grassi P; Procopio G; Pizzocaro G; Mariani L; Salvioni R
    Clin Genitourin Cancer; 2015 Aug; 13(4):385-391.e1. PubMed ID: 25726505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Y-encoded TSPY protein: a significant marker potentially plays a role in the pathogenesis of testicular germ cell tumors.
    Li Y; Tabatabai ZL; Lee TL; Hatakeyama S; Ohyama C; Chan WY; Looijenga LH; Lau YF
    Hum Pathol; 2007 Oct; 38(10):1470-81. PubMed ID: 17521702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of CD66b positive tumor-infiltrating neutrophils in testicular germ cell tumor.
    Yamada Y; Nakagawa T; Sugihara T; Horiuchi T; Yoshizaki U; Fujimura T; Fukuhara H; Urano T; Takayama K; Inoue S; Kume H; Homma Y
    BMC Cancer; 2016 Nov; 16(1):898. PubMed ID: 27863478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissue.
    Tirabosco R; Mangham DC; Rosenberg AE; Vujovic S; Bousdras K; Pizzolitto S; De Maglio G; den Bakker MA; Di Francesco L; Kalil RK; Athanasou NA; O'Donnell P; McCarthy EF; Flanagan AM
    Am J Surg Pathol; 2008 Apr; 32(4):572-80. PubMed ID: 18301055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive tissue markers in testicular germ cell tumors: Immunohistochemical expression of MLH1 and REV-7 proteins.
    Spinos T; Zografos E; Koutsoukos K; Zagouri F; Kosmas C; Driva TS; Goutas D; Gakiopoulou C; Agrogiannis G; Theochari E; Tzavara C; Lazaris AC
    Int Urol Nephrol; 2024 Jun; 56(6):1887-1898. PubMed ID: 38285100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of germ cell tumors with somatic type malignancy: pathological features, prognostic factors and survival outcomes.
    Rice KR; Magers MJ; Beck SD; Cary KC; Einhorn LH; Ulbright TM; Foster RS
    J Urol; 2014 Nov; 192(5):1403-9. PubMed ID: 24952240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors.
    Fankhauser CD; Roth L; Grossmann NC; Kranzbühler B; Eberli D; Sulser T; Moch H; Bode PK; Beyer J; Hermanns T
    BMC Cancer; 2019 Aug; 19(1):802. PubMed ID: 31412792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
    Toner GC; Geller NL; Lin SY; Bosl GJ
    Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.